254 related articles for article (PubMed ID: 33810957)
21. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
22. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
[TBL] [Abstract][Full Text] [Related]
23. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
24. Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease.
Vega GL; Grundy SM
J Lipid Res; 1984 Jun; 25(6):580-92. PubMed ID: 6747462
[TBL] [Abstract][Full Text] [Related]
25. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.
Eliasson B; Gudbjörnsdottir S; Zethelius B; Eeg-Olofsson K; Cederholm J;
Eur J Prev Cardiol; 2014 Nov; 21(11):1420-8. PubMed ID: 23774274
[TBL] [Abstract][Full Text] [Related]
26. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile.
Kaneva AM; Potolitsyna NN; Bojko ER
Arch Physiol Biochem; 2017 Feb; 123(1):16-22. PubMed ID: 27347637
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study.
Bertrand C; Saulnier PJ; Potier L; Croyal M; Blanchard V; Gand E; Ragot S; Schneider F; Bocock O; Baillet-Blanco L; Velho G; Marre M; Roussel R; Rigalleau V; Hadjadj S; Mohammedi K;
Diabetologia; 2021 Mar; 64(3):668-680. PubMed ID: 33409569
[TBL] [Abstract][Full Text] [Related]
29. The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China.
Qin Z; Zhou K; Li Y; Cheng W; Wang Z; Wang J; Gao F; Yang L; Xu Y; Wu Y; He H; Zhou Y
Cardiovasc Diabetol; 2020 Feb; 19(1):23. PubMed ID: 32085772
[TBL] [Abstract][Full Text] [Related]
30. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
31. Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease-a comparison in the MONICA/KORA study.
Huth C; Bauer A; Zierer A; Sudduth-Klinger J; Meisinger C; Roden M; Peters A; Koenig W; Herder C; Thorand B
Cardiovasc Diabetol; 2020 Mar; 19(1):32. PubMed ID: 32164753
[TBL] [Abstract][Full Text] [Related]
32. Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus.
Sprandel MC; Hueb WA; Segre A; Ramires JA; Kalil-Filho R; Maranhão RC
Cardiovasc Diabetol; 2015 Aug; 14():107. PubMed ID: 26268997
[TBL] [Abstract][Full Text] [Related]
33. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.
Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB
J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698
[TBL] [Abstract][Full Text] [Related]
34. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study.
Hoogeveen RC; Gaubatz JW; Sun W; Dodge RC; Crosby JR; Jiang J; Couper D; Virani SS; Kathiresan S; Boerwinkle E; Ballantyne CM
Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1069-77. PubMed ID: 24558110
[TBL] [Abstract][Full Text] [Related]
35. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.
Sierra-Johnson J; Fisher RM; Romero-Corral A; Somers VK; Lopez-Jimenez F; Ohrvik J; Walldius G; Hellenius ML; Hamsten A
Eur Heart J; 2009 Mar; 30(6):710-7. PubMed ID: 18676970
[TBL] [Abstract][Full Text] [Related]
36. Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.
Yubero-Serrano EM; Alcalá-Diaz JF; Gutierrez-Mariscal FM; Arenas-de Larriva AP; Peña-Orihuela PJ; Blanco-Rojo R; Martinez-Botas J; Torres-Peña JD; Perez-Martinez P; Ordovas JM; Delgado-Lista J; Gómez-Coronado D; Lopez-Miranda J
Cardiovasc Diabetol; 2021 Mar; 20(1):72. PubMed ID: 33766036
[TBL] [Abstract][Full Text] [Related]
37. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein B is not superior to non-high-density lipoprotein cholesterol for dyslipidemic classification of glycated hemoglobin-defined diabetic patients.
Xie J; Hu S
Medicine (Baltimore); 2018 Oct; 97(42):e12896. PubMed ID: 30335016
[TBL] [Abstract][Full Text] [Related]
39. Lipid assessment, metabolic syndrome and coronary heart disease risk.
Arsenault BJ; Després JP; Stroes ES; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
Eur J Clin Invest; 2010 Dec; 40(12):1081-93. PubMed ID: 20701625
[TBL] [Abstract][Full Text] [Related]
40. Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins.
Rasouli M; Kiasari AM
Clin Chem Lab Med; 2006; 44(1):43-50. PubMed ID: 16375584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
